Opdivo and Yervoy improve cure rates in resected stage 3/4 melanoma compared to placebo, with Opdivo showing superior efficacy. CheckMate 238 and EORTC 18071 trials reveal Opdivo's cure rate advantage ...

Opdivo and Yervoy are immunotherapy drugs that may be used together to treat certain types of advanced cancer. They can boost treatment efficacy and improve life expectancy. These drugs have several ...

Combining Opdivo and Yervoy is an effective treatment option for certain advanced cancers. You may find it helpful to explore specific details about this drug combination, including its uses, side ...

Opdivo plus Yervoy in the neoadjuvant setting reduced the risk for recurrence, progression or death, potentially offering patients with stage 3 melanoma a new standard of care. Neoadjuvant (primary ...

PRINCETON, N.J.--(BUSINESS WIRE)-- Bristol Myers Squibb (NYSE: BMY) today announced that Opdivo (nivolumab) plus Yervoy (ipilimumab) continued to demonstrate long-term survival results in the Phase 3 ...

Forbes contributors publish independent expert analyses and insights. Joshua Cohen is a Boston-based writer who covers health policy. The treatment consisted of two cycles of immunotherapy before ...

Ontario becomes the first province to list the combination under the new FAST pilot program, supporting timely access for eligible patients "For thousands of Ontarians facing a cancer diagnosis, fast ...

(Reuters) -Bristol Myers Squibb said on Wednesday a combination of Opdivo and Yervoy met the main goal of a late-stage study evaluating it as an initial treatment for a type of liver cancer. The ...

The U.S. Food and Drug Administration (FDA) on Tuesday approved Bristol Myers Squibb & Co’s (NYSE:BMY) Opdivo (nivolumab) plus Yervoy (ipilimumab) as a first-line treatment of adult and pediatric ...

is now publicly reimbursed in Ontario for the first-line treatment of adult patients with unresectable or advanced hepatocellular carcinoma (HCC) who meet specific clinical criteria. 1 "For every ...